ThermoGenesis (THMO) 10-Q 14 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 12, 2018
Document Information [Line Items]
Entity Registrant Name	CESCA THERAPEUTICS INC.
Entity Central Index Key	811,212
Trading Symbol	kool
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		21,649,147
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 2,220,000	$ 3,513,000
Accounts receivable, net of allowance for doubtful accounts of $335,000 ($274,000 at December 31, 2017)	2,090,000	1,687,000
Accounts receivable – related party		862,000
Inventories, net of reserves of $142,000 ($1,069,000 at December 31, 2017)	4,332,000	4,798,000
Prepaid expenses and other current assets	286,000	594,000
Total current assets	8,928,000	11,454,000
Restricted cash	1,000,000	1,000,000
Equipment, less accumulated depreciation	3,343,000	2,996,000
Goodwill	1,281,000	13,976,000
Intangible assets, net	6,996,000	21,629,000
Other assets	51,000	56,000
Total assets	21,599,000	51,111,000
Current liabilities:
Accounts payable	1,784,000	2,079,000
Accrued payroll and related expenses	384,000	532,000
Deferred revenue	527,000	384,000
Related party payable		606,000
Interest payable – related party	1,128,000	657,000
Other current liabilities	1,478,000	1,206,000
Total current liabilities	5,301,000	5,464,000
Convertible promissory note – related party, less debt discount of $6,400,000 at September 30, 2018 ($0 at December 31, 2017)	800,000	6,700,000
Derivative obligations	6,000	597,000
Noncurrent deferred tax liability	1,279,000	4,730,000
Other noncurrent liabilities	343,000	408,000
Total liabilities	7,729,000	17,899,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized; none issued and outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 21,649,147 issued and outstanding (10,872,428 at December 31, 2017)	22,000	11,000
Paid in capital in excess of par	235,691,000	221,371,000
Accumulated deficit	(220,276,000)	(187,640,000)
Accumulated other comprehensive income (loss)	8,000	(43,000)
Total Cesca Therapeutics Inc. stockholders’ equity	15,445,000	33,699,000
Noncontrolling interests	(1,575,000)	(487,000)
Total equity	13,870,000	33,212,000
Total liabilities and stockholders’ equity	$ 21,599,000	$ 51,111,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accounts receivable, allowance for doubtful accounts	$ 335,000	$ 274,000
Inventories, reserves	142,000	1,069,000
Debt discount	$ 6,400,000	$ 0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	21,649,147	10,872,428
Common stock, shares outstanding (in shares)	21,649,147	10,872,428

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net revenues	$ 3,113,000	$ 3,069,000	$ 6,984,000	$ 9,822,000
Cost of revenues	2,458,000	2,138,000	5,614,000	5,986,000
Gross profit	655,000	931,000	1,370,000	3,836,000
Expenses:
Sales and marketing	364,000	517,000	1,048,000	1,273,000
Research and development	611,000	1,063,000	2,560,000	2,196,000
General and administrative	1,615,000	1,701,000	6,256,000	6,302,000
Impairment of intangible asset			27,202,000	310,000
Total operating expenses	2,590,000	3,281,000	37,066,000	10,081,000
Loss from operations	(1,935,000)	(2,350,000)	(35,696,000)	(6,245,000)
Other income (expense):
Change in fair value of derivative instruments	24,000	(13,000)	591,000	100,000
Interest expense	(835,000)	(198,000)	(1,928,000)	(329,000)
Other expense	(18,000)	(26,000)	(63,000)	(37,000)
Total other expense	(829,000)	(237,000)	(1,400,000)	(266,000)
Loss before benefit for income taxes	(2,764,000)	(2,587,000)	(37,096,000)	(6,511,000)
Benefit for income taxes			3,451,000	673,000
Net loss	(2,764,000)	(2,587,000)	(33,645,000)	(5,838,000)
Loss attributable to noncontrolling interests	(175,000)	(237,000)	(1,088,000)	(237,000)
Net loss attributable to common stockholders	(2,589,000)	(2,350,000)	(32,557,000)	(5,601,000)
Net loss	(2,764,000)	(2,587,000)	(33,645,000)	(5,838,000)
Foreign currency translation adjustments	23,000	4,000	51,000	3,000
Comprehensive loss	(2,741,000)	(2,583,000)	(33,594,000)	(5,835,000)
Comprehensive loss attributable to noncontrolling interests	(175,000)	(237,000)	(1,088,000)	(237,000)
Comprehensive loss attributable to common stockholders	$ (2,566,000)	$ (2,346,000)	$ (32,506,000)	$ (5,598,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (0.12)	$ (0.24)	$ (2.01)	$ (0.57)
Weighted average common shares outstanding Basic and diluted (in shares)	22,114,473	9,950,776	16,174,365	9,902,480

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (33,645,000)	$ (5,838,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	506,000	517,000
Stock based compensation expense	475,000	560,000
Recovery of excess and slow-moving inventories	(126,000)	(117,000)
Bad debt expense	75,000	37,000
Amortization of debt discount	800,000
Change in fair value of derivative	(591,000)	(100,000)
Loss on disposal of equipment	451,000	176,000
Impairment of intangible asset	27,202,000	310,000
Deferred income tax benefit	3,451,000	673,000
Net change in operating assets and liabilities:
Accounts receivable	543,000	(413,000)
Inventories	336,000	(111,000)
Prepaid expenses and other assets	304,000	(11,000)
Accounts payable	(407,000)	(29,000)
Related party payable	(606,000)	606,000
Accrued payroll and related expenses	(147,000)	(1,192,000)
Deferred revenue	66,000	200,000
Other current liabilities	785,000	(94,000)
Other noncurrent liabilities	(1,000)	77,000
Net cash used in operating activities	(7,431,000)	(6,095,000)
Cash flows from investing activities:
Cash paid for business acquisition		(1,000,000)
Capital expenditures	(985,000)	(239,000)
Net cash used in investing activities	(985,000)	(1,239,000)
Cash flows from financing activities:
Proceeds from convertible promissory note – related party	500,000	5,000,000
Payment of financing cost		(13,000)
Payments on capital lease obligations	(28,000)	(42,000)
Proceeds from issuance of common stock and warrants, net	6,655,000
Cash paid for taxes on vested stock		(51,000)
Net cash provided by financing activities	7,127,000	4,894,000
Effects of foreign currency rate changes on cash and equivalents	(4,000)	5,000
Net change in cash and cash equivalents	(1,293,000)	(2,435,000)
Cash and cash equivalents at beginning of period	3,513,000	4,899,000
Cash and cash equivalents at end of period	2,220,000	2,464,000
Supplemental disclosures of cash flow information:
Cash paid for interest	664,000	5,000
Supplemental non-cash financing and investing information:
Subsidiary common stock issued for acquisition of net assets		2,499,000
Recording of beneficial conversion feature on debt	7,200,000
Transfer of inventories to equipment	420,000
Transfer of equipment to inventories	$ 172,000	$ 625,000

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Basis of Presentation and Summary of Significant Accounting Policies Organization and Basis of Presentation Cesca Therapeutics Inc. (“Cesca Therapeutics,” “Cesca,” the “Company”), a Delaware corporation, develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company was founded in 1986 ® ® Cesca is an affiliate of the Boyalife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine. Liquidity and Going Concern The Company has a Revolving Credit Agreement (the “Credit Agreement”) with Boyalife Asset Holding II, Inc. (Refer to Note 4 September 30, 2018, $7,200,000 $10,000,000 may On August 28, 2018, 1,000,000 $0.001 $0.18 2,965,000 $0.17 one $0.01 $684,000 $623,000 $61,000. September 30, 2018, none August 2018 February 26, 2019, On May 18, 2018, 6,475,001 2,691,666 $0.60 $5,500,000, $4,819,000 $681,000. one one one one one one one $0.60 five June 30, 2018, 2,691,666 May 2018 At September 30, 2018, $2,220,000 $3,627,000. September 30, 2018 $220,276,000. one The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company’s ability to do so. The condensed consolidated financial statements do not may Principles of Consolidation The condensed consolidated financial statements include the accounts of Cesca, its majority-owned subsidiary, ThermoGenesis, and its wholly-owned subsidiary TotipotentRX Cell Therapy, Pvt. Ltd (TotipotentRX). During the quarter ended September 30, 2018, Interim Reporting The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10 10 X. three nine September 30, 2018, not may December 31, 2018. 10 December 31, 2017. Reclassification Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Recently Issued Accounting Standards In August 2018, 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, not In June 2018, 2018 07, “Compensation-Stock Compensation (Topic 718 Improvements to Nonemployee S h a re-Based Payment Accounting” 718 December 15, 2018. not In January 2017, 2017 04, Simplifying the Test for Goodwill Impairment 2 December 15, 2019. January 1, 2017. not 2017 04 In February 2016, 2016 02, “Leases (Topic 842 2016 02 2016 02 December 15, 2018 July 2018, 2018 10 “Codification Improvements to Topic 842, 2016 02. 2016 02 July 2018, 2018 11, “Leases (Topic 842 ” January 1, 2019) 2016 02 Recently Adopted Accounting Standards In July 2017, No. 2017 11, Earnings Per Share (Topic 260 480 (Topic 815 (Part I) Accounting for Certain Financial Instruments with Down Round Features; (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception 2017 11 may no 2017 11 December 15, 2018, 2017 11 2017 11 April 1, 2018. April 1, 2018, not not April 16, 2018, 2017 11 4 Sequencing Policy Under Accounting Standard Codification (“ASC”) 815 40 35, 815 first 815, not On January 1, 2018, No. 2014 09, Revenue from Contracts with Customers (Topic 606 not January 1, 2018. January 1, 2018 No. 2014 09, not 605 $79,000 January 1, 2018 606, 606 Revenue Recognition Revenue is recognized based on the five 606: Step 1 Step 2 not Step 3 Step 4 one Step 5 Disaggregation of Revenue The Company’s primary revenue streams include device sales, service revenue from device maintenance contracts and clinical services. Device Sales Device sales include devices and consumables for BioArchive, AXP ® X not Service Revenue Service revenue consists primarily of maintenance contracts for BioArchive, AXP and X one two X one three not Clinical Services Service revenue in our Clinical Development Segment includes point of care procedures and cord blood processing and storage in our clinical segment. Point of care procedures are recognized when the procedures are performed. Cord blood processing and storage is recognized as the performance obligations are satisfied. Processing revenue is recognized when that performance obligation is completed immediately after the baby’s birth, with storage revenue recorded as deferred revenue and recognized ratably over time for up to 21 September 30, 2018, $251,000 may The following table summarizes the revenues of the Company’s reportable segments for the three nine September 30, 2018: Three Months Ended September 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,396,000 $ 70,000 $ -- $ 1,466,000 BioArchive 485,000 314,000 -- 799,000 Manual Disposables 254,000 -- -- 254,000 CAR-TXpress 517,000 -- -- 517,000 Other -- -- 23,000 23,000 Total Device Segment 2,652,000 384,000 23,000 3,059,000 Clinical Development Segment: Manual Disposables 8,000 -- -- 8,000 Bone Marrow -- 40,000 -- 40,000 Other -- 6,000 -- 6,000 Total Clinical Development 8,000 46,000 -- 54,000 Total $ 2,660,000 $ 430,000 $ 23,000 $ 3,113,000 Nine Months Ended September 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 2,930,000 $ 201,000 $ -- $ 3,131,000 BioArchive 1,357,000 969,000 -- 2,326,000 Manual Disposables 716,000 -- -- 716,000 CAR-TXpress 547,000 -- -- 547,000 Other 46,000 -- 56,000 102,000 Total Device Segment 5,596,000 1,170,000 56,000 6,822,000 Clinical Development Segment: Manual Disposables 31,000 -- -- 31,000 Bone Marrow -- 101,000 -- 101,000 Other -- 30,000 -- 30,000 Total Clinical Development 31,000 131,000 -- 162,000 Total $ 5,627,000 $ 1,301,000 $ 56,000 $ 6,984,000 Performance Obligations There is no no not may not Payments from domestic customers are normally due in two may 120 no Contract Balances The Company records a receivable when the titles of goods have transferred, maintenance contracts have been fully executed or when services have been rendered. Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not $284,000. $384,000 $527,000 nine September 30, 2018 Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2018 2019 2020 2021 and beyond Total Service revenue $ 323,000 $ 817,000 $ 253,000 $ 33,000 $ 1,426,000 Clinical revenue 3,000 14,000 14,000 219,000 250,000 Total $ 326,000 $ 831,000 $ 267,000 $ 252,000 $ 1,676,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Goodwill, Intangible Assets and Im pairment Assessments For goodwill and indefinite-lived intangible assets (clinical protocols), the carrying amounts are periodically reviewed for impairment (at least annually) and whenever events or changes in circumstances indicate that the carrying value of these assets may not 350 , ” Intangibles-Goodwill and Other ” not 50 2 In the second 2018, June 30, 2018 3 The Company recorded an impairment charge of $12,695,000 $14,507,000 nine September 30, 2018, Intangible Assets Goodwill Balance at December 31, 2017, net $ 21,629,000 $ 13,976,000 Amortization and foreign exchange (current year) (126,000 ) -- Impairment loss (14,507,000 ) (12,695,000 ) Balance at September 30, 2018, net $ 6,996,000 $ 1,281,000 Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer and chief operating officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Clinical Development Segment, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. ● The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device segment is operated through the Company’s ThermoGenesis subsidiary. Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no 2,965,000 three nine September 30, 2018 September 30: 2018 2017 Vested Series A warrants 404,412 404,412 Unvested Series A warrants 698,529 698,529 (1) Warrants – other 13,197,267 3,725,782 Convertible promissory note and accrued interest 46,266,667 -- Stock options 1,188,297 420,185 Restricted stock units -- 9,163 Total 61,755,172 5,258,071 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.

Note 3 - Acquisition of SynGen

Note 3 - Acquisition of SynGen Inc.	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Business Combination Disclosure [Text Block]	3. Acquisition of SynGen Inc. On July 7, 2017, The business acquired in the Transaction excludes certain assets and liabilities of SynGen that ThermoGenesis did not The acquisition was accounted for under the acquisition method of accounting for business combinations which requires, among other things, that the assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The consideration for the Transaction consisted of $1,000,000 2,000,000 20% $2,528,000. 2,000,000 first Supplemental Pro Forma Data The Company used the acquisition method of accounting to account for the SynGen acquisition and, accordingly, the results of SynGen are included in the Company’s consolidated financial statements for the period subsequent to the date of acquisition. For the three nine September 30, 2018, $517,000 $566,000 three nine September 30, 2017 January 1, 2017. Three Months Ended September 30, 2017 Nine Months Ended September 30, 2017 Net revenues $ 3,069,000 $ 10,207,000 Net loss $ (2,439,000 ) $ (6,399,000 ) Basic and diluted net loss per common share $ (0.22 ) $ (0.65 ) The unaudited pro forma financial information reflects certain adjustments related to the acquisition, such as the incremental amortization expense in connection with recording acquired identifiable intangible assets at fair value, the revised payroll expense associated with the new salaries of SynGen employees resulting from the acquisition, the elimination of SynGen expenses related to debt issuance costs, interest and other warrant related expenses, the elimination of the legal fees paid by both parties related to the litigation between Cesca and SynGen as ceasing the litigation was part of the Asset Acquisition Agreement and costs directly related to the acquisition.

Note 4 - Related Party Transact

Note 4 - Related Party Transactions	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	4. Related Party Transactions Convertible Promissory Note and Revolving Credit Agreement On March 6, 2017, $10,000,000 March 6, 2022 ( $7,200,000 September 30, 2018. The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued but unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% The Credit Agreement and Note were amended on April 16, 2018. ● The Lender was granted the right to convert, at any time, outstanding principal and accrued but unpaid interest under the Credit Agreement into shares of Common Stock at a conversion price equal to $1.61 90% 10 April 2018 ● If the Company after April 16, 2018 ● The Company has been granted the right to defer payment of the $657,000 December 31, 2017 December 31, 2018, $5.0 $657,000 May 2018. On May 7, 2018, No. 1 On May 18, 2018, $0.60 $1.61 $0.60. August 28, 2018, $0.18 $0.60 $0.18. The Maturity Date of the Amended Credit Agreement is subject to acceleration at the option of the Lender upon customary events of default, which include a breach of the Loan documents, termination of operations or bankruptcy. The Lender’s obligation to make advances under the Loan is subject to the Company’s representations and warranties in the Amended Credit Agreement continuing to be true at all times and there being no No The Company accounted for the Amended Credit Agreement as a loan modification. As discussed in Note 2, 2017 11 Accounting for Certain Financial Instruments with Down Round Features”. 2017 11 not not $7,200,000. $450,000 $800,000 three nine September 30, 2018. $350,000 The Company recorded interest expense of $385,000 $1,128,000, three nine September 30, 2018, $198,000 $329,000 three nine September 30, 2017, $1,128,000 $657,000 September 30, 2018 December 31, 2017, Distributor Agreement On August 21, 2017, ® ® ® ® ® The term of the agreement is for three two Revenues The Company recorded $267,000 $536,000 three nine September 30, 2018 $751,000 three nine September 30, 2017 Bill Payment Arrangement The Company entered into a bill payment arrangement whereby Boyalife Group Ltd. (Payor), the Company’s largest shareholder, agreed to pay the Company’s legal expenses payable to the Company’s attorney related to certain litigation involving SynGen (the “Bill Payment Arrangement”), although the Company remains jointly and severally liable for the payment of such legal fees. The terms of the Bill Payment Arrangement provided that the Company will reimburse Payor for any and all amounts paid by Payor in connection with the Bill Payment Arrangement under certain specified events. There is no $606,000 $606,000 May 2018.

Note 5 - Commitments and Contin

Note 5 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	5 . Commitments and Contingencies Financial Covenants Effective May 15, 2017, one not $2,000,000. October 31, 2018. Warranty The Company offers a warranty on all of its non-disposable products of one two The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the nine September 30, 2018 Balance at December 31, 2017 $ 291,000 Warranties issued during the period 78,000 Settlements made during the period (234,000 ) Changes in liability for pre-existing warranties during the period (24,000 ) Balance at September 30, 2018 $ 111,000 Contingencies and Restricted Cash In fiscal 2016, May 4, 2017, $1,000,000 August 2016. October 2017, $1,000,000 June 26, 2018. September 24, 2018, No no September 30, 2018. In the normal course of operations, the Company may September 30, 2018, may not

Note 6 - Derivative Obligations

Note 6 - Derivative Obligations	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	6. Derivative Obligations Series A Warrants Series A warrants to purchase 404,412 June 30, 2016. Series A September 30, 2018 December 31, 2017 Market price of common stock $ 0.32 $ 3.00 Expected volatility 102 % 107 % Contractual term (years) 2.4 3.2 Discount rate 2.84 % 1.99 % Dividend rate 0 % 0 % Exercise price $ 8.00 $ 8.00 Expected volatilities are based on the historical volatility of the Company’s common stock. Contractual term is based on remaining term of the respective warrants. The discount rate represents the yield on U.S. Treasury bonds with a maturity equal to the contractual term. The Company recorded a gain(loss) of $24,000 $591,000 three nine September 30, 2018, $13,000 $100,000 three nine September 30, 2017, The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of September 30, 2018 December 31, 2017: Derivative Obligation September 30, 2018 December 31, 2017 Balance $ 6,000 $ 597,000 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ 6,000 $ 597,000 The following table reflects the change in fair value of the Company’s derivative liabilities for the nine September 30, 2018: Amount Balance – December 31, 2017 $ 597,000 Change in fair value of derivative obligation (591,000 ) Balance – September 30, 2018 $ 6,000

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7. Stockholders’ Equity Common Stock On August 28, 2018, 1,000,000 $0.18 2,965,000 $0.17 one $0.01 $684,000 $623,000 $61,000. September 30, 2018, none August 2018 February 26, 2019, On May 18, 2018, 6,475,001 2,691,666 $0.60 $5,500,000, $4,819,000 $681,000. one one one one one one one $0.60 five 2,691,666 May 2018 second 2018. On March 28, 2018, 609,636 $2.27 $171,000, $1,213,000. 304,818 $2.68 six 5.5 Stock Based Compensation The Company recorded stock-based compensation of $175,000 $475,000 three nine September 30, 2018, $132,000 $560,000 three nine September 30, 2017, The following is a summary of option activity for the Company’s stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2017 1,156,027 $ 3.92 Granted 93,500 $ 2.63 Forfeited (33,860 ) $ 3.83 Expired (27,370 ) $ 4.83 Outstanding at September 30, 2018 1,188,297 $ 3.80 8.2 -- Vested and expected to vest at September 30, 2018 973,878 $ 3.98 7.9 -- Exercisable at September 30, 2018 306,646 $ 6.15 5.4 -- The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no nine September 30, 2018. The fair value of the Company’s stock options granted for the nine September 30, 2018 Expected life (years) 5.6 Risk-free interest rate 2.7 % Expected volatility 98 % Dividend yield 0 % Common Stock Restricted Units The following is a summary of restricted stock activity during the nine September 30, 2018: Weighted Average Number of Shares Grant Date Fair Value Balance at December 31, 2017 416 $ 17.60 Granted -- -- Vested (416 ) $ 17.60 Forfeited -- -- Outstanding at September 30, 2018 -- -- Warrants A summary of warrant activity for the nine September 30, 2018 Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2017 4,828,723 $9.37 Warrants granted 12,436,485 $0.51 Warrants canceled -- -- Warrants exercised -- -- Outstanding at September 30, 2018 17,265,208 $2.99 Exercisable at September 30, 2018 16,566,679 $2.78 At September 30, 2018, $919,000.

Note 8 - Segment Reporting

Note 8 - Segment Reporting	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	8. Segment Reporting The Company has two The Device Segment is a pioneer and market leader in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The Clinical Development Segment is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. The following tables summarize the operating results of the Company’s reportable segments: Three Months Ended September 30, 2018 Clinical Development Device Total Net revenues $ 54,000 $ 3,059,000 $ 3,113,000 Cost of revenues 75,000 2,383,000 2,458,000 Gross profit (21,000 ) 676,000 655,000 Operating expenses 621,000 1,969,000 2,590,000 Operating loss $ (642,000 ) $ (1,293,000 ) $ (1,935,000 ) Depreciation and amortization $ 74,000 $ 100,000 $ 174,000 Stock-based compensation expense $ 167,000 $ 8,000 $ 175,000 Three Months Ended September 30, 2017 Clinical Development Device Total Net revenues $ 126,000 $ 2,943,000 $ 3,069,000 Cost of revenues 120,000 2,018,000 2,138,000 Gross profit 6,000 925,000 931,000 Operating expenses 1,169,000 2,112,000 3,281,000 Operating loss $ (1,163,000 ) $ (1,187,000 ) $ (2,350,000 ) Depreciation and amortization $ 75,000 $ 85,000 $ 160,000 Stock-based compensation expense $ 85,000 $ 47,000 $ 132,000 Nine Months Ended September 30, 2018 Clinical Development Device Total Net revenues $ 162,000 $ 6,822,000 $ 6,984,000 Cost of revenues 195,000 5,419,000 5,614,000 Gross profit (33,000 ) 1,403,000 1,370,000 Operating expenses 30,208,000 6,858,000 37,066,000 Operating loss $ (30,241,000 ) $ (5,455,000 ) $ (35,696,000 ) Depreciation and amortization $ 210,000 $ 296,000 $ 506,000 Impairment Charges $ 27,202,000 $ -- $ 27,202,000 Stock-based compensation expense $ 387,000 $ 88,000 $ 475,000 Total assets $ 11,386,000 $ 10,213,000 $ 21,599,000 Nine Months Ended September 30, 2017 Clinical Development Device Total Net revenues $ 392,000 $ 9,430,000 $ 9,822,000 Cost of revenues 355,000 5,631,000 5,986,000 Gross profit 37,000 3,799,000 3,836,000 Operating expenses 5,049,000 5,032,000 10,081,000 Operating loss $ (5,012,000 ) $ (1,233,000 ) $ (6,245,000 ) Depreciation and amortization $ 301,000 $ 216,000 $ 517,000 Stock-based compensation expense $ 336,000 $ 224,000 $ 560,000

Note 9 - Income Taxes

Note 9 - Income Taxes	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	9. Income Taxes The following table summarizes our benefit for income taxes and our effective tax rates for the three nine September 30, 2018. Three Months Ended September 30, 2018 Nine Months Ended September 30, 2018 Net loss before benefit for income taxes $ (2,764,000 ) $ (37,096,000 ) Benefit for income taxes -- 3,451,000 Effective tax rate 0 % 9.3 % For the nine September 30, 2018, $3,451,000 nine September 30, 2018. For the nine September 30, 2018, $3,451,000. The Tax Cuts and Jobs Act (Jobs Act) legislation was passed in December 2017, 35% 21% September 30, 2018, not not may may may

Note 10 - Subsequent Event

Note 10 - Subsequent Event	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	10 . Subsequent Event On October 15, 2018, $311,000. fourth 2018.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards In August 2018, 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, not In June 2018, 2018 07, “Compensation-Stock Compensation (Topic 718 Improvements to Nonemployee S h a re-Based Payment Accounting” 718 December 15, 2018. not In January 2017, 2017 04, Simplifying the Test for Goodwill Impairment 2 December 15, 2019. January 1, 2017. not 2017 04 In February 2016, 2016 02, “Leases (Topic 842 2016 02 2016 02 December 15, 2018 July 2018, 2018 10 “Codification Improvements to Topic 842, 2016 02. 2016 02 July 2018, 2018 11, “Leases (Topic 842 ” January 1, 2019) 2016 02 Recently Adopted Accounting Standards In July 2017, No. 2017 11, Earnings Per Share (Topic 260 480 (Topic 815 (Part I) Accounting for Certain Financial Instruments with Down Round Features; (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception 2017 11 may no 2017 11 December 15, 2018, 2017 11 2017 11 April 1, 2018. April 1, 2018, not not April 16, 2018, 2017 11 4
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenue is recognized based on the five 606: Step 1 Step 2 not Step 3 Step 4 one Step 5 Disaggregation of Revenue The Company’s primary revenue streams include device sales, service revenue from device maintenance contracts and clinical services. Device Sales Device sales include devices and consumables for BioArchive, AXP ® X not Service Revenue Service revenue consists primarily of maintenance contracts for BioArchive, AXP and X one two X one three not Clinical Services Service revenue in our Clinical Development Segment includes point of care procedures and cord blood processing and storage in our clinical segment. Point of care procedures are recognized when the procedures are performed. Cord blood processing and storage is recognized as the performance obligations are satisfied. Processing revenue is recognized when that performance obligation is completed immediately after the baby’s birth, with storage revenue recorded as deferred revenue and recognized ratably over time for up to 21 September 30, 2018, $251,000 may The following table summarizes the revenues of the Company’s reportable segments for the three nine September 30, 2018: Three Months Ended September 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,396,000 $ 70,000 $ -- $ 1,466,000 BioArchive 485,000 314,000 -- 799,000 Manual Disposables 254,000 -- -- 254,000 CAR-TXpress 517,000 -- -- 517,000 Other -- -- 23,000 23,000 Total Device Segment 2,652,000 384,000 23,000 3,059,000 Clinical Development Segment: Manual Disposables 8,000 -- -- 8,000 Bone Marrow -- 40,000 -- 40,000 Other -- 6,000 -- 6,000 Total Clinical Development 8,000 46,000 -- 54,000 Total $ 2,660,000 $ 430,000 $ 23,000 $ 3,113,000 Nine Months Ended September 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 2,930,000 $ 201,000 $ -- $ 3,131,000 BioArchive 1,357,000 969,000 -- 2,326,000 Manual Disposables 716,000 -- -- 716,000 CAR-TXpress 547,000 -- -- 547,000 Other 46,000 -- 56,000 102,000 Total Device Segment 5,596,000 1,170,000 56,000 6,822,000 Clinical Development Segment: Manual Disposables 31,000 -- -- 31,000 Bone Marrow -- 101,000 -- 101,000 Other -- 30,000 -- 30,000 Total Clinical Development 31,000 131,000 -- 162,000 Total $ 5,627,000 $ 1,301,000 $ 56,000 $ 6,984,000 Performance Obligations There is no no not may not Payments from domestic customers are normally due in two may 120 no Contract Balances The Company records a receivable when the titles of goods have transferred, maintenance contracts have been fully executed or when services have been rendered. Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not $284,000. $384,000 $527,000 nine September 30, 2018 Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2018 2019 2020 2021 and beyond Total Service revenue $ 323,000 $ 817,000 $ 253,000 $ 33,000 $ 1,426,000 Clinical revenue 3,000 14,000 14,000 219,000 250,000 Total $ 326,000 $ 831,000 $ 267,000 $ 252,000 $ 1,676,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill, Intangible Assets and Im pairment Assessments For goodwill and indefinite-lived intangible assets (clinical protocols), the carrying amounts are periodically reviewed for impairment (at least annually) and whenever events or changes in circumstances indicate that the carrying value of these assets may not 350 , ” Intangibles-Goodwill and Other ” not 50 2 In the second 2018, June 30, 2018 3 The Company recorded an impairment charge of $12,695,000 $14,507,000 nine September 30, 2018, Intangible Assets Goodwill Balance at December 31, 2017, net $ 21,629,000 $ 13,976,000 Amortization and foreign exchange (current year) (126,000 ) -- Impairment loss (14,507,000 ) (12,695,000 ) Balance at September 30, 2018, net $ 6,996,000 $ 1,281,000
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3
Segment Reporting, Policy [Policy Text Block]	Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer and chief operating officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Clinical Development Segment, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. ● The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device segment is operated through the Company’s ThermoGenesis subsidiary.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no 2,965,000 three nine September 30, 2018 September 30: 2018 2017 Vested Series A warrants 404,412 404,412 Unvested Series A warrants 698,529 698,529 (1) Warrants – other 13,197,267 3,725,782 Convertible promissory note and accrued interest 46,266,667 -- Stock options 1,188,297 420,185 Restricted stock units -- 9,163 Total 61,755,172 5,258,071 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,396,000 $ 70,000 $ -- $ 1,466,000 BioArchive 485,000 314,000 -- 799,000 Manual Disposables 254,000 -- -- 254,000 CAR-TXpress 517,000 -- -- 517,000 Other -- -- 23,000 23,000 Total Device Segment 2,652,000 384,000 23,000 3,059,000 Clinical Development Segment: Manual Disposables 8,000 -- -- 8,000 Bone Marrow -- 40,000 -- 40,000 Other -- 6,000 -- 6,000 Total Clinical Development 8,000 46,000 -- 54,000 Total $ 2,660,000 $ 430,000 $ 23,000 $ 3,113,000 Nine Months Ended September 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 2,930,000 $ 201,000 $ -- $ 3,131,000 BioArchive 1,357,000 969,000 -- 2,326,000 Manual Disposables 716,000 -- -- 716,000 CAR-TXpress 547,000 -- -- 547,000 Other 46,000 -- 56,000 102,000 Total Device Segment 5,596,000 1,170,000 56,000 6,822,000 Clinical Development Segment: Manual Disposables 31,000 -- -- 31,000 Bone Marrow -- 101,000 -- 101,000 Other -- 30,000 -- 30,000 Total Clinical Development 31,000 131,000 -- 162,000 Total $ 5,627,000 $ 1,301,000 $ 56,000 $ 6,984,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Remainder of 2018 2019 2020 2021 and beyond Total Service revenue $ 323,000 $ 817,000 $ 253,000 $ 33,000 $ 1,426,000 Clinical revenue 3,000 14,000 14,000 219,000 250,000 Total $ 326,000 $ 831,000 $ 267,000 $ 252,000 $ 1,676,000
Schedule of Intangible Assets and Goodwill [Table Text Block]	Intangible Assets Goodwill Balance at December 31, 2017, net $ 21,629,000 $ 13,976,000 Amortization and foreign exchange (current year) (126,000 ) -- Impairment loss (14,507,000 ) (12,695,000 ) Balance at September 30, 2018, net $ 6,996,000 $ 1,281,000
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2018 2017 Vested Series A warrants 404,412 404,412 Unvested Series A warrants 698,529 698,529 (1) Warrants – other 13,197,267 3,725,782 Convertible promissory note and accrued interest 46,266,667 -- Stock options 1,188,297 420,185 Restricted stock units -- 9,163 Total 61,755,172 5,258,071

Note 3 - Acquisition of SynGe_2

Note 3 - Acquisition of SynGen Inc. (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Business Acquisition, Pro Forma Information [Table Text Block]	Three Months Ended September 30, 2017 Nine Months Ended September 30, 2017 Net revenues $ 3,069,000 $ 10,207,000 Net loss $ (2,439,000 ) $ (6,399,000 ) Basic and diluted net loss per common share $ (0.22 ) $ (0.65 )

Note 5 - Commitments and Cont_2

Note 5 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Balance at December 31, 2017 $ 291,000 Warranties issued during the period 78,000 Settlements made during the period (234,000 ) Changes in liability for pre-existing warranties during the period (24,000 ) Balance at September 30, 2018 $ 111,000

Note 6 - Derivative Obligatio_2

Note 6 - Derivative Obligations (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Series A September 30, 2018 December 31, 2017 Market price of common stock $ 0.32 $ 3.00 Expected volatility 102 % 107 % Contractual term (years) 2.4 3.2 Discount rate 2.84 % 1.99 % Dividend rate 0 % 0 % Exercise price $ 8.00 $ 8.00
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Derivative Obligation September 30, 2018 December 31, 2017 Balance $ 6,000 $ 597,000 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ 6,000 $ 597,000
Derivative Instruments, Gain (Loss) [Table Text Block]	Amount Balance – December 31, 2017 $ 597,000 Change in fair value of derivative obligation (591,000 ) Balance – September 30, 2018 $ 6,000

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2017 1,156,027 $ 3.92 Granted 93,500 $ 2.63 Forfeited (33,860 ) $ 3.83 Expired (27,370 ) $ 4.83 Outstanding at September 30, 2018 1,188,297 $ 3.80 8.2 -- Vested and expected to vest at September 30, 2018 973,878 $ 3.98 7.9 -- Exercisable at September 30, 2018 306,646 $ 6.15 5.4 --
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Expected life (years) 5.6 Risk-free interest rate 2.7 % Expected volatility 98 % Dividend yield 0 %
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Weighted Average Number of Shares Grant Date Fair Value Balance at December 31, 2017 416 $ 17.60 Granted -- -- Vested (416 ) $ 17.60 Forfeited -- -- Outstanding at September 30, 2018 -- --
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2017 4,828,723 $9.37 Warrants granted 12,436,485 $0.51 Warrants canceled -- -- Warrants exercised -- -- Outstanding at September 30, 2018 17,265,208 $2.99 Exercisable at September 30, 2018 16,566,679 $2.78

Note 8 - Segment Reporting (Tab

Note 8 - Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	Three Months Ended September 30, 2018 Clinical Development Device Total Net revenues $ 54,000 $ 3,059,000 $ 3,113,000 Cost of revenues 75,000 2,383,000 2,458,000 Gross profit (21,000 ) 676,000 655,000 Operating expenses 621,000 1,969,000 2,590,000 Operating loss $ (642,000 ) $ (1,293,000 ) $ (1,935,000 ) Depreciation and amortization $ 74,000 $ 100,000 $ 174,000 Stock-based compensation expense $ 167,000 $ 8,000 $ 175,000 Three Months Ended September 30, 2017 Clinical Development Device Total Net revenues $ 126,000 $ 2,943,000 $ 3,069,000 Cost of revenues 120,000 2,018,000 2,138,000 Gross profit 6,000 925,000 931,000 Operating expenses 1,169,000 2,112,000 3,281,000 Operating loss $ (1,163,000 ) $ (1,187,000 ) $ (2,350,000 ) Depreciation and amortization $ 75,000 $ 85,000 $ 160,000 Stock-based compensation expense $ 85,000 $ 47,000 $ 132,000 Nine Months Ended September 30, 2018 Clinical Development Device Total Net revenues $ 162,000 $ 6,822,000 $ 6,984,000 Cost of revenues 195,000 5,419,000 5,614,000 Gross profit (33,000 ) 1,403,000 1,370,000 Operating expenses 30,208,000 6,858,000 37,066,000 Operating loss $ (30,241,000 ) $ (5,455,000 ) $ (35,696,000 ) Depreciation and amortization $ 210,000 $ 296,000 $ 506,000 Impairment Charges $ 27,202,000 $ -- $ 27,202,000 Stock-based compensation expense $ 387,000 $ 88,000 $ 475,000 Total assets $ 11,386,000 $ 10,213,000 $ 21,599,000 Nine Months Ended September 30, 2017 Clinical Development Device Total Net revenues $ 392,000 $ 9,430,000 $ 9,822,000 Cost of revenues 355,000 5,631,000 5,986,000 Gross profit 37,000 3,799,000 3,836,000 Operating expenses 5,049,000 5,032,000 10,081,000 Operating loss $ (5,012,000 ) $ (1,233,000 ) $ (6,245,000 ) Depreciation and amortization $ 301,000 $ 216,000 $ 517,000 Stock-based compensation expense $ 336,000 $ 224,000 $ 560,000

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Three Months Ended September 30, 2018 Nine Months Ended September 30, 2018 Net loss before benefit for income taxes $ (2,764,000 ) $ (37,096,000 ) Benefit for income taxes -- 3,451,000 Effective tax rate 0 % 9.3 %

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)	Aug. 28, 2018	May 18, 2018	Mar. 28, 2018	Jun. 30, 2018	Sep. 30, 2018	Dec. 31, 2017
Stock Issued During Period, Shares, New Issues			609,636
Common Stock, Par or Stated Value Per Share					$ 0.001	$ 0.001
Shares Issued, Price Per Share			$ 2.27
Class of Warrant or Right, Issued During Period					12,436,485
Payments of Stock Issuance Costs		$ 681,000	$ 171,000
Units Issued, Price per Unit		$ 0.60
Proceeds from Issuance or Sale of Equity, Total		$ 5,500,000
Proceeds from Issuance or Sale of Equity, Net		$ 4,819,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance					$ 2,220,000	$ 3,513,000
Working Capital					3,627,000
Retained Earnings (Accumulated Deficit), Ending Balance					(220,276,000)	$ (187,640,000)
Common Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.60
Warrants and Rights Outstanding, Term		5 years
Units [Member]
Number of Units Issued		6,475,001
Convertible Units, Number of Common Shares Called by Each Unit		1
Convertible Units, Number of Common Warrants Called by Each Unit		1
Units [Member] | Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Pre-funded Units [member]
Number of Units Issued		2,691,666
Convertible Units, Number of Common Warrants Called by Each Unit		1
Convertible Units, Number of Pre-funded Warrants Called by Each Unit		1
Number of Units Exercised				2,691,666
Pre-funded Units [member] | Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Pre-funded Units [member] | Pre-funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Private Placement [Member]
Stock Issued During Period, Shares, New Issues	1,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001
Shares Issued, Price Per Share	$ 0.18
Class of Warrant or Right, Issued During Period	2,965,000
Warrants Issued, Price Per Warrant	$ 0.17
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Proceeds from Issuance of Private Placement	$ 684,000
Proceeds from Issuance of Private Placement, Net	623,000
Payments of Stock Issuance Costs	$ 61,000
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Long-term Line of Credit, Total					7,200,000
Line of Credit Facility, Maximum Borrowing Capacity					$ 10,000,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended	9 Months Ended
	Sep. 30, 2018USD ($)shares	Sep. 30, 2018USD ($)shares	Sep. 30, 2017shares	Jan. 01, 2018USD ($)	Dec. 31, 2017USD ($)
Maximum Period Of Agreement		21 years
Contract with Customer, Liability, Revenue Recognized	$ 284,000	$ 251,000
Contract with Customer, Liability, Current	$ 527,000	527,000			$ 384,000
Goodwill, Impairment Loss		12,695,000
Impairment of Intangible Assets (Excluding Goodwill), Total		$ 14,507,000
Number of Reportable Segments		2
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares		61,755,172	5,258,071
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares	2,965,000	2,965,000
Retained Earnings [Member] | Accounting Standards Update 2014-09 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption				$ (79,000)

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net revenues	$ 3,113,000	$ 3,069,000	$ 6,984,000	$ 9,822,000
Device [Member]
Net revenues	3,059,000		6,822,000
Device [Member] | AXP [Member]
Net revenues	1,466,000		3,131,000
Device [Member] | BioArchive [Member]
Net revenues	799,000		2,326,000
Device [Member] | Manual Disposables [Member]
Net revenues	254,000		716,000
Device [Member] | CAR-TXpress [Member]
Net revenues	517,000		547,000
Device [Member] | Other Subsegments [Member]
Net revenues	23,000		102,000
Device [Member] | Bone Marrow [Member]
Net revenues	40,000		101,000
Clinical Development [Member]
Net revenues	54,000		162,000
Clinical Development [Member] | Manual Disposables [Member]
Net revenues	8,000		31,000
Clinical Development [Member] | Other Subsegments [Member]
Net revenues	6,000		30,000
Device Revenue [Member]
Net revenues	2,660,000		5,627,000
Device Revenue [Member] | Device [Member]
Net revenues	2,652,000		5,596,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues	1,396,000		2,930,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues	485,000		1,357,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues	254,000		716,000
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	517,000		547,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues			46,000
Device Revenue [Member] | Device [Member] | Bone Marrow [Member]
Net revenues
Device Revenue [Member] | Clinical Development [Member]
Net revenues	8,000		31,000
Device Revenue [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues	8,000		31,000
Device Revenue [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues
Service [Member]
Net revenues	430,000		1,301,000
Service [Member] | Device [Member]
Net revenues	384,000		1,170,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues	70,000		201,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues	314,000		969,000
Service [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues
Service [Member] | Device [Member] | Other Subsegments [Member]
Net revenues
Service [Member] | Device [Member] | Bone Marrow [Member]
Net revenues	40,000		101,000
Service [Member] | Clinical Development [Member]
Net revenues	46,000		131,000
Service [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues	6,000		30,000
Other [Member]
Net revenues	23,000		56,000
Other [Member] | Device [Member]
Net revenues	23,000		56,000
Other [Member] | Device [Member] | AXP [Member]
Net revenues
Other [Member] | Device [Member] | BioArchive [Member]
Net revenues
Other [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	23,000		56,000
Other [Member] | Device [Member] | Bone Marrow [Member]
Net revenues
Other [Member] | Clinical Development [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)	Sep. 30, 2018USD ($)
Revenue	$ 1,676,000
Service [Member]
Revenue	1,426,000
Clinical Revenue [Member]
Revenue	$ 250,000

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details)	Sep. 30, 2018USD ($)
Revenue	$ 1,676,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-12-31
Revenue	326,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-12-31
Revenue	831,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-12-31
Revenue	267,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-12-31
Revenue	252,000
Service [Member]
Revenue	1,426,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-12-31
Revenue	323,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-12-31
Revenue	817,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-12-31
Revenue	253,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-12-31
Revenue	33,000
Clinical Revenue [Member]
Revenue	250,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-12-31
Revenue	3,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-12-31
Revenue	14,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-12-31
Revenue	14,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-12-31
Revenue	$ 219,000

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Goodwill and Intangible Assets (Details)	9 Months Ended
	Sep. 30, 2018USD ($)
Intangible assets at December 31, 2017, net	$ 21,629,000
Intangible assets, amortization and foreign exchange (current year)	(126,000)
Intangible assets, impairment loss	(14,507,000)
Intangible assets at September 30, 2018, net	6,996,000
Goodwill at December 31, 2017, net	13,976,000
Goodwill, foreign exchange (current year)
Goodwill, impairment loss	(12,695,000)
Goodwill at September 30, 2018, net	$ 1,281,000

Note 2 - Summary of Significa_8

Note 2 - Summary of Significant Accounting Policies - Calculation for Basic and Diluted Earnings Per Share (Details) - shares		9 Months Ended
		Sep. 30, 2018	Sep. 30, 2017
Anti-dilutive securities (in shares)		61,755,172	5,258,071
Vested Series A Warrants [Member]
Anti-dilutive securities (in shares)		404,412	404,412
Unvested Series A Warrants [Member]
Anti-dilutive securities (in shares)	[1]	698,529	698,529
Warrant, Other [Member]
Anti-dilutive securities (in shares)		13,197,267	3,725,782
Convertible Promissory Note and Accrued Interest [Member]
Anti-dilutive securities (in shares)		46,266,667
Employee Stock Option [Member]
Anti-dilutive securities (in shares)		1,188,297	420,185
Restricted Stock Units (RSUs) [Member]
Anti-dilutive securities (in shares)			9,163
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

Note 3 - Acquisition of SynGe_3

Note 3 - Acquisition of SynGen Inc. (Details Textual) - USD ($)	Jul. 07, 2017	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Payments to Acquire Businesses, Gross				$ 1,000,000
SynGen [Member]
Payments to Acquire Businesses, Gross	$ 1,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	2,000,000
Percentage Of Common Stock Issued To Acquiree Shareholders	20.00%
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 2,528,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual		$ 517,000	$ 566,000

Note 3 - Acquisition of SynGe_4

Note 3 - Acquisition of SynGen Inc.- Supplemental Pro Forma Data (Details) - SynGen [Member] - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017
Net revenues	$ 3,069,000	$ 10,207,000
Net loss	$ (2,439,000)	$ (6,399,000)
Basic and diluted net loss per common share (in dollars per share)	$ (0.22)	$ (0.65)

Note 4 - Related Party Transa_2

Note 4 - Related Party Transactions (Details Textual) - USD ($)	Aug. 21, 2017	Mar. 06, 2017	Jun. 30, 2018	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Aug. 28, 2018	May 18, 2018	Apr. 16, 2018	Apr. 01, 2018	Dec. 31, 2017
Units Issued, Price per Unit										$ 0.60
Amortization of Debt Discount (Premium)				$ 450,000			$ 800,000
Interest Expense, Total				835,000		$ 198,000	1,928,000	329,000
Accounting Standards Update 2017-11 [Member]
Amortization of Debt Discount (Premium)				350,000			350,000
Adjustments for New Accounting Principle, Early Adoption [Member] | Accounting Standards Update 2017-11 [Member]
Debt Instrument, Unamortized Discount, Total												$ 7,200,000
Boyalife Investment Fund II, Inc. [Member] | Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price									$ 0.18	$ 0.60	$ 1.61
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity				10,000,000			10,000,000
Proceeds from Long-term Lines of Credit							7,200,000
Debt Instrument, Interest Rate, Stated Percentage		22.00%
Debt Instrument, Convertible, Percentage of Conversion Price		90.00%
Debt Instrument, Number of Trading Days Prior to the Maturity Date		10 days
Interest Payable				1,128,000			1,128,000				$ 657,000		$ 657,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total			$ 657,000
Interest Expense, Total				385,000		198,000	1,128,000	329,000
Boyalife W.S.N. [Member]
Distributor Agreement Term	3 years
Distributor Agreement, Renewal Term	2 years
Revenue from Related Parties				$ 267,000		$ 751,000	$ 536,000	$ 751,000
Boyalife Group Ltd. [Member] | Legal Expenses Reimbursement [Member]
Related Party Transaction, Amounts of Transaction					$ 606,000

Note 5 - Commitments and Cont_3

Note 5 - Commitments and Contingencies (Details Textual) - USD ($)	May 04, 2017	Oct. 31, 2017	Sep. 30, 2018
Payment Terms, Severance Compensation			1 year
Short Term Investment Minimum			$ 2,000,000
Litigation Related to Strategic Advisory Services [Member]
Loss Contingency, Damages Sought, Value	$ 1,000,000
Loss Contingency, Negotiation Condition Bond		$ 1,000,000
Loss Contingency Accrual, Ending Balance			$ 0
Minimum [Member]
Period Of Warranty On Products			1 year
Maximum [Member]
Period Of Warranty On Products			2 years

Note 5 - Commitments and Cont_4

Note 5 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details)	9 Months Ended
	Sep. 30, 2018USD ($)
Balance at December 31, 2017	$ 291,000
Warranties issued during the period	78,000
Settlements made during the period	(234,000)
Changes in liability for pre-existing warranties during the period	(24,000)
Balance at September 30, 2018	$ 111,000

Note 6 - Derivative Obligatio_3

Note 6 - Derivative Obligations (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Jun. 30, 2016
Class of Warrant or Right, Outstanding	17,265,208		17,265,208		4,828,723
Derivative, Gain (Loss) on Derivative, Net, Total	$ 24,000	$ (13,000)	$ 591,000	$ 100,000
Series A Warrant [Member]
Class of Warrant or Right, Outstanding						404,412

Note 6 - Derivative Obligatio_4

Note 6 - Derivative Obligations - Fair Value Assumptions (Details) - Series A Warrant [Member]	Sep. 30, 2018	Dec. 31, 2017
Measurement Input, Share Price [Member]
Valuation assumption	0.32	3
Measurement Input, Price Volatility [Member]
Valuation assumption	1.02	1.07
Measurement Input, Expected Term [Member]
Valuation assumption	2.4	3.2
Measurement Input, Discount Rate [Member]
Valuation assumption	0.0284	0.0199
Measurement Input, Expected Dividend Rate [Member]
Valuation assumption	0	0
Measurement Input, Exercise Price [Member]
Valuation assumption	8	8

Note 6 - Derivative Obligatio_5

Note 6 - Derivative Obligations - Fair Value Hierarchy (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Derivative obligations	$ 6,000	$ 597,000
Fair Value, Inputs, Level 1 [Member]
Derivative obligations
Fair Value, Inputs, Level 2 [Member]
Derivative obligations
Fair Value, Inputs, Level 3 [Member]
Derivative obligations	$ 6,000	$ 597,000

Note 6 - Derivative Obligatio_6

Note 6 - Derivative Obligations - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Balance			$ 597,000
Change in fair value of derivative obligation	$ (24,000)	$ 13,000	(591,000)	$ (100,000)
Balance	$ 6,000		$ 6,000

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual) - USD ($)	Aug. 28, 2018	May 18, 2018	Mar. 28, 2018	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock Issued During Period, Shares, New Issues			609,636
Shares Issued, Price Per Share			$ 2.27
Class of Warrant or Right, Issued During Period							12,436,485
Payments of Stock Issuance Costs		$ 681,000	$ 171,000
Units Issued, Price per Unit		$ 0.60
Proceeds from Issuance or Sale of Equity, Total		$ 5,500,000
Proceeds from Issuance or Sale of Equity, Net		$ 4,819,000
Proceeds from Issuance of Common Stock, Net			$ 1,213,000				$ 6,655,000
Allocated Share-based Compensation Expense, Total					$ 175,000	$ 132,000	$ 475,000	$ 560,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							0
Class of Warrant or Right, Outstanding, Intrinsic Value					$ 919,000		$ 919,000
Common Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.60
Warrants and Rights Outstanding, Term		5 years
Warrants Issused in Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.68
Warrants and Rights Outstanding, Term			5 years 182 days
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			304,818
Units [Member]
Number of Units Issued		6,475,001
Convertible Units, Number of Common Shares Called by Each Unit		1
Convertible Units, Number of Common Warrants Called by Each Unit		1
Units [Member] | Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Pre-funded Units [member]
Number of Units Issued		2,691,666
Convertible Units, Number of Common Warrants Called by Each Unit		1
Convertible Units, Number of Pre-funded Warrants Called by Each Unit		1
Number of Units Exercised				2,691,666
Pre-funded Units [member] | Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Pre-funded Units [member] | Pre-funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Private Placement [Member]
Stock Issued During Period, Shares, New Issues	1,000,000
Shares Issued, Price Per Share	$ 0.18
Class of Warrant or Right, Issued During Period	2,965,000
Warrants Issued, Price Per Warrant	$ 0.17
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Proceeds from Issuance of Private Placement	$ 684,000
Proceeds from Issuance of Private Placement, Net	623,000
Payments of Stock Issuance Costs	$ 61,000

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details)	9 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares
Outstanding, options (in shares) | shares	1,156,027
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 3.92
Granted, options (in shares) | shares	93,500
Granted, weighted average exercise price, options (in dollars per share) | $ / shares	$ 2.63
Forfeited (in shares) | shares	(33,860)
Forfeited (in dollars per share) | $ / shares	$ 3.83
Expired, options (in shares) | shares	(27,370)
Expired, weighted average exercise price, options (in dollars per share) | $ / shares	$ 4.83
Outstanding, options (in shares) | shares	1,188,297
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 3.80
Outstanding, weighted average remaining contractual life, options (Year)	8 years 73 days
Outstanding, aggregate intrinsic value, options | $
Vested and Expected to Vest, options (in shares) | shares	973,878
Vested and Expected to Vest, weighted average exercise price, options (in dollars per share) | $ / shares	$ 3.98
Vested and Expected to Vest, weighted average remaining contractual life, options (Year)	7 years 328 days
Vested and Expected to Vest, aggregate intrinsic value, options | $
Exercisable, options (in shares) | shares	306,646
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 6.15
Exercisable, weighted average remaining contractual life, options (Year)	5 years 146 days
Exercisable, aggregate intrinsic value, options | $

Note 7 - Stockholders' Equity_3

Note 7 - Stockholders' Equity - Schedule of Assumptions (Details)	9 Months Ended
	Sep. 30, 2018
Expected life (years) (Year)	5 years 219 days
Risk-free interest rate	2.70%
Expected volatility	98.00%
Dividend yield	0.00%

Note 7 - Stockholders' Equity_4

Note 7 - Stockholders' Equity - Restricted Stock Unit Activity Granted to Employees (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Balance, Number of Shares (in shares) | shares	416
Balance, Weighted Average Grant Date Fair Value, (in dollars per share) | $ / shares	$ 17.60
Granted, Number of Shares (in shares) | shares
Granted, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares
Vested, Number of Shares (in shares) | shares	(416)
Vested, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares	$ 17.60
Forfeited, Number of Shares (in shares) | shares
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares
Balance, Number of Shares (in shares) | shares
Balance, Weighted Average Grant Date Fair Value, (in dollars per share) | $ / shares

Note 7 - Stockholders' Equity_5

Note 7 - Stockholders' Equity - Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Balance (in shares) | shares	4,828,723
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 9.37
Warrants granted (in shares) | shares	12,436,485
Warrants granted, weighted average exercise price (in dollars per share) | $ / shares	$ 0.51
Warrants exercised (in shares) | shares
Warrants exercised (cashless), weighted average exercise price (in dollars per share) | $ / shares
Balance (in shares) | shares	17,265,208
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 2.99
Exercisable at September 30, 2018 (in shares) | shares	16,566,679
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 2.78

Note 8 - Segment Reporting (Det

Note 8 - Segment Reporting (Details Textual)	9 Months Ended
	Sep. 30, 2018
Number of Reportable Segments	2

Note 8 - Segment Reporting - Su

Note 8 - Segment Reporting - Summary of Operating Results by Reportable Segments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Net revenues	$ 3,113,000	$ 3,069,000	$ 6,984,000	$ 9,822,000
Cost of revenues	2,458,000	2,138,000	5,614,000	5,986,000
Gross profit	655,000	931,000	1,370,000	3,836,000
Operating expenses	2,590,000	3,281,000	37,066,000	10,081,000
Operating loss	(1,935,000)	(2,350,000)	(35,696,000)	(6,245,000)
Depreciation and amortization	174,000	160,000	506,000	517,000
Stock-based compensation expense	175,000	132,000	475,000	560,000
Operating loss	(1,935,000)	(2,350,000)	(35,696,000)	(6,245,000)
Impairment of intangible asset			27,202,000	310,000
Total assets	21,599,000		21,599,000		$ 51,111,000
Clinical Development [Member]
Net revenues	54,000		162,000
Clinical Development [Member] | Operating Segments [Member]
Net revenues	54,000	126,000	162,000	392,000
Cost of revenues	75,000	120,000	195,000	355,000
Gross profit	(21,000)	6,000	(33,000)	37,000
Operating expenses	621,000	1,169,000	30,208,000	5,049,000
Operating loss	(642,000)	(1,163,000)	(30,241,000)	(5,012,000)
Depreciation and amortization	74,000	75,000	210,000	301,000
Stock-based compensation expense	167,000	85,000	387,000	336,000
Operating loss	(642,000)	(1,163,000)	(30,241,000)	(5,012,000)
Impairment of intangible asset			27,202,000
Total assets	11,386,000		11,386,000
Device [Member]
Net revenues	3,059,000		6,822,000
Device [Member] | Operating Segments [Member]
Net revenues	3,059,000	2,943,000	6,822,000	9,430,000
Cost of revenues	2,383,000	2,018,000	5,419,000	5,631,000
Gross profit	676,000	925,000	1,403,000	3,799,000
Operating expenses	1,969,000	2,112,000	6,858,000	5,032,000
Operating loss	(1,293,000)	(1,187,000)	(5,455,000)	(1,233,000)
Depreciation and amortization	100,000	85,000	296,000	216,000
Stock-based compensation expense	8,000	47,000	88,000	224,000
Operating loss	(1,293,000)	$ (1,187,000)	(5,455,000)	$ (1,233,000)
Impairment of intangible asset
Total assets	$ 10,213,000		$ 10,213,000

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2018
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability fom Impairment of Intangible Assets	$ (3,451,000)
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		21.00%

Note 9 - Income Taxes - Summary

Note 9 - Income Taxes - Summary of Provision (Benefit) for Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net loss before benefit for income taxes	$ (2,764,000)	$ (2,587,000)	$ (37,096,000)	$ (6,511,000)
Benefit for income taxes			$ 3,451,000	$ 673,000
Effective tax rate	0.00%		9.30%

Note 10 - Subsequent Event (Det

Note 10 - Subsequent Event (Details Textual)	Oct. 15, 2018USD ($)
Subsequent Event [Member]
Severance Liability	$ 311,000